Atea Pharmaceuticals, Inc. Common Stock vs. Eli Lilly & Co.
Atea Pharmaceuticals, Inc. Common Stock and Eli Lilly & Co. are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| AVIR | LLY | |
|---|---|---|
| Market Cap | $417.87 million | $1.02 trillion |
| Revenue (TTM) | — | — |
| Net Income (TTM) | $-165,289,000 | — |
LLY leads on 1 of 1 size & scale factors.
Valuation
| AVIR | LLY | |
|---|---|---|
| Price / Book | 2.05 | — |
AVIR and LLY split the valuation factors evenly.
Profitability
| AVIR | LLY | |
|---|---|---|
| Return on Equity | -80.96% | — |
AVIR and LLY split the profitability factors evenly.
Dividend
| AVIR | LLY | |
|---|---|---|
| Dividend Yield | — | 0.60% |
AVIR and LLY split the dividend factors evenly.
Risk & Sentiment
| AVIR | LLY | |
|---|---|---|
| Short Interest | 0.39% | 1.29% |
AVIR leads on 1 of 1 risk & sentiment factors.
Dig deeper: AVIR overview, AVIR financials, LLY overview, LLY financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.